Clinical efficacy of unani herbal formulation garlina against primary hyperlipidemia

ABSTRACT

Primary hyperlipidemia and atherosclerosis are correlated to each other and these are major cibdutuuibs of coronary artery diseases. The objective of the study was to evaluate the efficacy of polyherbal Unani medicine [Garlina] a well-known herbal formulation to be used for Primary hyperlipidemia. This was an open, randomized, prospective, multicenter study on human subjects of 6 months duration. After the laboratory investigations for fasting plasma lipids of the suspected subjects, 25 subjects were identified, randomized and received the drug. The subjects were diagnosed and classified according to the international recommended levels of plasma lipids [PL] as total cholesterol levels were borderline high [200-239 mg/dL], triglycerides [TGs] were high [200-499 mg/dL], high density lipoprotein [HDL] were desirable but not optimal [41-59 mg/dL] while low density lipoproteins [LDL] were borderline high [130-159 mg/dL]. After 8 weeks administration of Garlina tablets 500 mg twice-a-day, the total cholesterol levels were reduced to 166.48+/- 35.59 mg/dL from 224.04+/-9.16 mg/dL, triglyceride levels were also reduced to 144.28+/- 37.11 mg/dL from 217.28+/-73.54 mg/dL at the base line, low density lipoprotein levels were reduced to S7.52+/-40.17 mg/dL from 133.96+/- 54.00 mg/dL while high density lipoprotein level was increased to 56.20±8.66 mg/dL from 48.28+/-10.57 mg/dL. The findings from this study demonstrated that there was significant difference [p<0.05] before and after treatment with Garlina [500 rqg] as mean lipid profiles of test group administered 1 tablet b.d. after meals. This is clearly evident that Garlina possesses a significant hypolipidemic therapeutic value for the treatment of primary hyperlipidemia